The company completed its submission for FDA review of a supplemental New Drug Application (sNDA) for FILSPARI in FSGS, potentially positioning it as the first approved therapy for this condition. If ...

Travere Therapeutics (TVTX) reported $81.73 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 97.6%. EPS of -$0.47 for the same period compares to -$1.76 a ...

Olin Corporation announced financial results for the first quarter ended . First quarter 2025 reported net income was $1.4 million, or $0.01 per diluted share, which compares to first quarter 2024 ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2025 financial results and provided a corporate update.

The European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard marketing ...

Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor are pleased to announce that the European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard ...

European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive recommendation ...

CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) are pleased to announce that the European Commission has approved ...

The company’s products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin ...

Autistic kid hands holding puzzle jigsaw and word autism, mental health concept. Autism spectrum, disorder. World autism awareness day Parents might be able help detect autism earlier than ever in ...